CY1122634T1 - Μεθοδοι και συνθεσεις για thn παρασκευη αερολυματων - Google Patents

Μεθοδοι και συνθεσεις για thn παρασκευη αερολυματων

Info

Publication number
CY1122634T1
CY1122634T1 CY20191100668T CY191100668T CY1122634T1 CY 1122634 T1 CY1122634 T1 CY 1122634T1 CY 20191100668 T CY20191100668 T CY 20191100668T CY 191100668 T CY191100668 T CY 191100668T CY 1122634 T1 CY1122634 T1 CY 1122634T1
Authority
CY
Cyprus
Prior art keywords
methods
compositions
preparation
aerosols
thn
Prior art date
Application number
CY20191100668T
Other languages
English (en)
Inventor
Erik Depla
Mauro Sergi
Peter Casteels
Original Assignee
Ablynx N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ablynx N.V. filed Critical Ablynx N.V.
Publication of CY1122634T1 publication Critical patent/CY1122634T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μεθόδους για την παρασκευή αερολύματος. Ειδικότερα, η παρούσα εφεύρεση παρέχει μεθόδους για την παρασκευή αερολύματος μονών μεταβλητών περιοχών ανοσοσφαιρίνης όπου η ποσότητα σχηματισμού συσσωματωμάτων μειώνεται σημαντικά. Η εφεύρεση περαιτέρω παρέχει αερολύματα τα οποία παρασκευάζονται με τις μεθόδους της εφεύρεσης, καθώς επίσης συνθέσεις για χρήση στις μεθόδους της εφεύρεσης. Η εφεύρεση περαιτέρω αναφέρεται σε μεθόδους για τις παρασκευές τέτοιων συνθέσεων, σε περιέκτες, κιτ και συστήματα αποδέσμευσης αερολύματος που αποτελούνται από τέτοιες συνθέσεις και σε χρήσεις αυτών.
CY20191100668T 2010-02-11 2019-06-26 Μεθοδοι και συνθεσεις για thn παρασκευη αερολυματων CY1122634T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30344710P 2010-02-11 2010-02-11
US201061426610P 2010-12-23 2010-12-23
PCT/EP2011/052024 WO2011098552A2 (en) 2010-02-11 2011-02-11 Methods and compositions for the preparation of aerosols

Publications (1)

Publication Number Publication Date
CY1122634T1 true CY1122634T1 (el) 2021-03-12

Family

ID=43899571

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100668T CY1122634T1 (el) 2010-02-11 2019-06-26 Μεθοδοι και συνθεσεις για thn παρασκευη αερολυματων

Country Status (17)

Country Link
US (3) US9713589B2 (el)
EP (2) EP3501499B1 (el)
JP (3) JP5951508B2 (el)
CN (2) CN105380904A (el)
AU (1) AU2011214299B2 (el)
CA (1) CA2787718C (el)
CY (1) CY1122634T1 (el)
DK (1) DK2533761T3 (el)
ES (2) ES2931330T3 (el)
HK (1) HK1222128A1 (el)
HR (1) HRP20191071T1 (el)
HU (1) HUE044292T2 (el)
LT (1) LT2533761T (el)
PL (2) PL3501499T3 (el)
PT (2) PT2533761T (el)
SI (1) SI2533761T1 (el)
WO (1) WO2011098552A2 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3004707C (en) 2009-09-02 2022-05-31 Synedgen Inc. Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds
PT2533761T (pt) 2010-02-11 2019-06-17 Ablynx Nv Métodos e composições para a preparação de aerossóis
SG10202010355PA (en) 2010-03-12 2020-11-27 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
EA201490047A1 (ru) * 2011-06-17 2014-08-29 Берг Ллк Ингаляционные фармацевтические композиции
US20150216977A1 (en) * 2012-09-18 2015-08-06 Adocia Stable pharmaceutical composition, comprising an aqueous solution of an antibody-derived therapeutically active protein
AU2014233055B2 (en) 2013-03-15 2018-08-09 Board Of Regents, The University Of Texas System Inhibition of pulmonary fibrosis with nutlin-3a and peptides
NL1040254C2 (en) * 2013-05-17 2014-11-24 Ablynx Nv Stable formulations of immunoglobulin single variable domains and uses thereof.
CA2943376C (en) * 2014-04-03 2022-06-14 Medizinische Hochschule Hannover Nebulization of immunoglobulin
AU2015314775A1 (en) * 2014-09-11 2017-03-30 Synedgen, Inc. Compositions and methods of use thereof
SG11201702688UA (en) * 2014-10-10 2017-04-27 Ablynx Nv Methods of treating rsv infections
TR201909589T4 (tr) * 2014-10-10 2019-07-22 Ablynx Nv Solunum hastalıklarının aerosol terapisinde kullanıma yönelik inhalasyon cihazı.
EP4056194A1 (en) * 2015-02-27 2022-09-14 Board of Regents, The University of Texas System Polypeptide therapeutics and uses thereof
EP3452505A1 (en) 2016-05-02 2019-03-13 Ablynx NV Treatment of rsv infection
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
TWI802576B (zh) 2017-06-02 2023-05-21 德商馬克專利公司 與ａｄａｍｔｓ結合之免疫球蛋白
JP7496826B2 (ja) 2018-09-10 2024-06-07 ラング セラピューティクス，エルエルシー Ｃａｖ－１タンパク質の修飾ペプチドフラグメント及び線維症の治療におけるその使用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US5938117A (en) 1991-04-24 1999-08-17 Aerogen, Inc. Methods and apparatus for dispensing liquids as an atomized spray
EP2192131A1 (en) 1992-08-21 2010-06-02 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
FR2708622B1 (fr) 1993-08-02 1997-04-18 Raymond Hamers Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides.
US6205999B1 (en) 1995-04-05 2001-03-27 Aerogen, Inc. Methods and apparatus for storing chemical compounds in a portable inhaler
US5586550A (en) 1995-08-31 1996-12-24 Fluid Propulsion Technologies, Inc. Apparatus and methods for the delivery of therapeutic liquids to the respiratory system
US6014970A (en) 1998-06-11 2000-01-18 Aerogen, Inc. Methods and apparatus for storing chemical compounds in a portable inhaler
US5758637A (en) 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US6085740A (en) 1996-02-21 2000-07-11 Aerogen, Inc. Liquid dispensing apparatus and methods
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
DK0937140T3 (da) 1996-06-27 2008-01-28 Vlaams Interuniv Inst Biotech Antistofmolekyler, som interagerer specifikt med et målmolekyles aktive sted eller klöft
EP1027439B1 (en) 1997-10-27 2010-03-17 Bac Ip B.V. Multivalent antigen-binding proteins
AU3596599A (en) 1998-01-26 1999-08-09 Unilever Plc Method for producing antibody fragments
AU3041100A (en) 1999-01-05 2000-07-24 Unilever Plc Binding of antibody fragments to solid supports
DE60013767T3 (de) 1999-01-19 2009-07-09 Unilever N.V. Verfahren zur herstellung von antikörperfragmenten
WO2000065057A1 (en) 1999-04-22 2000-11-02 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
AU1859201A (en) 1999-11-29 2001-06-12 Unilever Plc Immobilisation of proteins
WO2001044301A1 (en) 1999-11-29 2001-06-21 Unilever Plc Immobilized single domain antigen-binding molecules
ES2324280T3 (es) 2000-03-14 2009-08-04 Unilever N.V. Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
AU2002229639A1 (en) 2000-12-13 2002-06-24 De Haard, Johannes Joseph Wilhelmus Camelidae antibody arrays
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7371849B2 (en) 2001-09-13 2008-05-13 Institute For Antibodies Co., Ltd. Methods of constructing camel antibody libraries
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
AU2002351896A1 (en) 2001-12-11 2003-06-23 Ablynx N.V. Method for displaying loops from immunoglobulin domains in different contexts
AU2002360068B2 (en) 2001-12-21 2009-09-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
CA2471645A1 (en) 2002-01-03 2003-07-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Immunoconjugates useful for treatment of tumours
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
AU2003286004A1 (en) 2002-11-08 2004-06-07 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
CN101412759A (zh) 2003-01-10 2009-04-22 埃博灵克斯股份有限公司 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用
US7461263B2 (en) 2003-01-23 2008-12-02 Unspam, Llc. Method and apparatus for a non-revealing do-not-contact list system
WO2005018629A1 (en) 2003-08-12 2005-03-03 Yarbrough William M Treatment for acne vulgaris and method of use
ES2352697T3 (es) 2003-11-07 2011-02-22 Ablynx N.V. Anticuerpos de dominio único de camelidae vhh dirigidos contra el receptor del factor de crecimiento epidérmico y usos de los mismos.
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
CA2583017A1 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease
CA2595682A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EP2172484A3 (en) 2005-05-18 2010-05-19 Ablynx N.V. Serum albumin binding proteins
CN101213214B (zh) 2005-05-20 2014-06-25 埃博灵克斯股份有限公司 针对冯威勒布兰特因子的单一结构域vhh抗体
WO2007085815A2 (en) * 2006-01-24 2007-08-02 Domantis Limited Ligands that bind il-4 and/or il-13
US20110059101A9 (en) 2006-03-13 2011-03-10 Ablynx N.V. Amino Acid Sequences Directed Against Il-6 And Polypetides Comprising The Same For The Treatment Of Diseases And Disorders Associated With Il-6 Mediated Signalling
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
WO2008028977A2 (en) 2006-09-08 2008-03-13 Ablynx N.V. Serum albumin binding proteins with long half-lives
EP2081960B1 (en) 2006-10-27 2018-06-27 Ablynx N.V. Intranasal delivery of polypeptides and proteins
US8907065B2 (en) 2006-12-15 2014-12-09 Ablynx N.V. Polypeptides that modulate the interaction between cells of the immune system
US20100062004A1 (en) 2006-12-19 2010-03-11 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
EP2514767A1 (en) 2006-12-19 2012-10-24 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
US20100166734A1 (en) 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
WO2008077945A2 (en) 2006-12-22 2008-07-03 Ablynx N.V. Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
JP5419709B2 (ja) * 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
AU2008219216A1 (en) 2007-02-21 2008-08-28 Ablynx N.V. Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
WO2008142165A1 (en) 2007-05-24 2008-11-27 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
CA2687903C (en) 2007-05-24 2016-09-13 Ablynx N.V. Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
WO2009068625A2 (en) 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
JP2011506396A (ja) 2007-12-13 2011-03-03 グラクソ グループ リミテッド 肺送達用組成物
AU2009254501B2 (en) 2008-06-05 2014-07-31 Ablynx N.V. Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
LT2438087T (lt) 2009-06-05 2017-08-25 Ablynx N.V. Trivalenčiai nanokūno konstruktai prieš žmogaus respiratorinį sincitinį virusą (hrsv), skirti kvėpavimo takų infekcijų profilaktikai ir (arba) gydymui
ES2831323T3 (es) 2009-09-03 2021-06-08 Ablynx Nv Formulaciones estables de polipéptidos y usos de las mismas
PT2533761T (pt) 2010-02-11 2019-06-17 Ablynx Nv Métodos e composições para a preparação de aerossóis

Also Published As

Publication number Publication date
US20210346287A1 (en) 2021-11-11
JP2018083839A (ja) 2018-05-31
CA2787718C (en) 2018-05-15
CN102753148A (zh) 2012-10-24
EP3501499B1 (en) 2022-09-07
JP2016193923A (ja) 2016-11-17
SI2533761T1 (sl) 2019-08-30
JP6283064B2 (ja) 2018-02-21
WO2011098552A3 (en) 2012-03-29
HUE044292T2 (hu) 2019-10-28
JP5951508B2 (ja) 2016-07-13
JP7019433B2 (ja) 2022-02-15
US12083219B2 (en) 2024-09-10
US20130019860A1 (en) 2013-01-24
HRP20191071T1 (hr) 2019-09-20
AU2011214299A1 (en) 2012-08-02
ES2738114T3 (es) 2020-01-20
CN105380904A (zh) 2016-03-09
ES2931330T3 (es) 2022-12-28
PT3501499T (pt) 2022-11-22
AU2011214299B2 (en) 2014-07-31
EP2533761A2 (en) 2012-12-19
WO2011098552A2 (en) 2011-08-18
DK2533761T3 (da) 2019-06-24
EP2533761B1 (en) 2019-03-27
PL2533761T3 (pl) 2019-09-30
JP2013519654A (ja) 2013-05-30
US20170333344A1 (en) 2017-11-23
LT2533761T (lt) 2019-07-10
PL3501499T3 (pl) 2023-01-09
CN102753148B (zh) 2018-01-26
EP3501499A1 (en) 2019-06-26
US9713589B2 (en) 2017-07-25
HK1222128A1 (zh) 2017-06-23
PT2533761T (pt) 2019-06-17
CA2787718A1 (en) 2011-08-18
US11007146B2 (en) 2021-05-18

Similar Documents

Publication Publication Date Title
CY1122634T1 (el) Μεθοδοι και συνθεσεις για thn παρασκευη αερολυματων
CY1121832T1 (el) Μονοκλωνικα αντισωματα κατα του παραγοντα αναπτυξεως και διαφοροποιησεως 15(gdf-15)
IL275114B (en) Antibody constructs for cdh19 and cd3 binding sites, preparations containing them, methods for their preparation and uses thereof
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CY1123958T1 (el) Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης
CY1120471T1 (el) Αντισωματα κατα του cd70
EP3786183A3 (en) Antigen binding constructs to cd3
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
AU2018253639A1 (en) Compositions and methods for antibodies targeting EPO
AU2014247175A8 (en) Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5 and methods of use
MX2016008098A (es) Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
EA201790293A3 (ru) Антитела, направленные против icos, и их применения
UA112416C2 (uk) Антитіло до fap і способи його застосування
MX342034B (es) Proteinas monovalentes que se unen a antigenos.
MX2014009289A (es) Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer.
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
EP2560684A4 (en) FIBRONECTIN TYPE III DOMAIN MULTIMERIC SCAFFOLDS
CA2872308A1 (en) Novel ha binding agents
EA201590887A1 (ru) Композиция
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
WO2013063613A3 (en) Methods and compositions related to intracellular neutralization by igg
MX360245B (es) Composiciones que comprenden inmunoglobulinas de tipo secretor.